Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

A new approach to migraines - A review of rimegepant; its merits, synthesis, and pharmacological characteristics

28 September 2022, Version 1
Review
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Migraines in the modern day represent a significant problem, however, the current treatment options come with significant risks. This paper reviews rimegepant, its pharmacological characteristics, and possible synthetic pathways, focusing on ease of synthesis, green chemistry, and scalability. The review reveals a biocatalytic approach to be a promising candidate for industrial scale-up with relatively mild conditions.

Keywords

rimegepant
migraines
biocatalysis
stereochemistry
stereoselective synthesis
CGRP receptor antagonists
transaminase

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Sep 28, 2022 Version 1

Metrics

1,028
819
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
The content is available under CC BY NC 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2022-9d5l4
D O I: 10.26434/chemrxiv-2022-9d5l4 [opens in a new tab]

Author’s competing interest statement

The author(s) have declared they have no conflict of interest with regard to this content

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share